Additionally, apart from its ability to decrease nesfatin-1 abundance, the therapeutic effect of RES on NAFLD rats might also be related to an imbalance in the expression level of Copine 6 and key proteins in the Wnt/β-catenin signaling pathway in the hippocampus and PFC. This evidence concerns the gene NUCB2 and metabolic dysfunction-associated steatotic liver disease.